Mr. Scott Cormack has over two decades of diverse experience in the biotechnology industry in executive management and venture capital.
Scott is the founding President and CEO of OncoGenex Technologies Inc. and became its full-time President and CEO in January, 2002. He has led OncoGenex through significant corporate milestones including serial rounds of private financing; leading the corporation through transition from pre-clinical through completion of multiple phase 2 clinical trials and through the development of a robust product candidate pipeline. In August, 2008 OncoGenex Technologies Inc. completed a successful reverse take over of Sonus Pharmaceuticals, Inc. to become a NASDAQ listed biotechnology company with Scott becoming the Chief Executive Officer of OncoGenex Pharmaceuticals, Inc.
In October, 2009, Scott was named Canada's Pacific Ernst & Young's Entrepreneur of the Year®, a high profile business award recognizing entrepreneurs that are building successful, dynamic businesses. In December, 2009, Scott led his team to complete a global collaboration and license agreement with global generic medicines giant, Teva Pharmaceutical Industries Ltd., to support the final stage of development of OGX-011. Scott has created a solid foundation for OncoGenex to maximize the broad potential of OGX-011 and a robust pipeline of product candidates, potentially bringing important treatment options to cancer patients.
Stephen Anderson BA, MBA, CA
Chief Financial Officer
Mr. Anderson is Chief Financial Officer at OncoGenex with 17 years of financial experience with both public and private companies. Most recently, he was Chief Financial Officer at Perceptronix Medical Inc., a medical diagnostic company focused on the early detection of lung cancer. Prior to Perceptronix, he was with Westport Innovations Inc., spanning roles as Controller, Vice President, Finance and most recently Chief Financial Officer. During his time at Westport, he was involved in raising over $200 million, listing on the Toronto Stock Exchange, closing several acquisitions and forming Cummins Westport Inc., a commercial joint venture with a major US manufacturer. He has consulted for other technology companies, primarily in the areas of financing, operations and strategy. Mr. Anderson has also previously worked with Discovery Capital Corporation, a Vancouver-based venture capital firm specializing in technology and health and life sciences, the Jim Pattison Group and KPMG. He has a Bachelor of Arts and a Master of Business Administration degrees, both from the University of British Columbia and is a Chartered Accountant.
Dr. Cindy Jacobs Ph.D, MD
Executive Vice President and Chief Medical Officer
Dr. Jacobs is Executive Vice President and Chief Medical Officer at OncoGenex. She received her Ph.D. from Washington State University and her MD from the University of Washington Medical School. She has over twenty years of biotechnology experience in preclinical development, pharmacokinetic/drug metabolism studies, toxicology studies, Phase 1-4 clinical trials in a variety of therapeutic areas, regulatory affairs, biostatistics, data management, medical information and quality assurance. At Immunex (now known as Amgen), Dr. Jacobs successfully lead the preclinical development of soluble cytokine receptors and fusion proteins into the clinic which later resulted in the approval of the TNF Receptor Fusion protein for use in rheumatoid arthritis, currently on the market as Enbrel. Subsequently, she became Vice-President of Clinical Research at CellPro Inc. and coordinated an international team achieving both European and US approvals of the CEPRATE SC Stem Cell System for use in bone marrow and peripheral blood transplantation. Her team achieved two US approvals for the CEPRATE SC System, as a device in combination with a monoclonal antibody for selection of CD34+ cells. Prior to joining OncoGenex, Dr. Jacobs was the Senior Vice-President of Clinical Development and Chief Medical Officer at Corixa (now a subsidiary of Glaxo-Smith-Kline). During her six years at Corixa, her team obtained Canadian approval for Melacine, a cancer vaccine for Melanoma, and two US approvals for BEXXAR, a radioimmunotherapy for refractory and relapsed non-Hodgkin's lymphoma.
Dr. Monica Krieger Ph.D
Vice President of Regulatory Affairs
Dr. Krieger is Vice President, Regulatory Affairs at OncoGenex. She received a Ph.D from Rutgers University and an MBA from the Darden School at the University of Virginia. Her 24 years of experience in regulatory and clinical affairs includes 23 years at five biotechnology companies in Seattle. At Genetic Systems Corporation (currently owned by BioRad Laboratories) she was Vice President, Regulatory, Clinical and Quality Assurance. During her nine years there she led a team that obtained approval for blood banking tests for HIV-1, HIV-2 and hepatitis, as well as approval of other tests for infectious disease. Subsequently she spent seven years at CellPro, Inc. where she worked with Dr. Jacobs to obtain two approvals from the FDA for the CEPRATE ® SC, a stem cell selection device. The first approval was based on data from patients with breast cancer and the second demonstrated the utility of the device in tumour removal in patients with multiple myeloma. At NeoRx, Dr. Krieger led the regulatory group developing two oncology products: one for the treatment of non-Hodgkin's lymphoma and the second for multiple myeloma. Most recently, she spent six years at Corixa Corporation as Vice-President, Regulatory Affairs. There she worked with Dr. Jacobs, and the clinical/regulatory team obtained Canadian approval for Melacine, a vaccine for the treatment of melanoma as well as two US approvals for BEXXAR, a radioimmunotherapy for non-Hodgkin's lymphoma.
Martin Gleave MD, FRCSC, FACS
Chief Scientific Officer
Dr. Gleave is a Distinguished Professor in the Department of Urologic Sciences at the University of British Columbia, Director of the Vancouver Prostate Center, Director of Research for the Department of Urologic Sciences at UBC, and Chairs the Genito-Urinary Tumour Group Chair at BC Cancer Agency. He has published more than 230 peer-reviewed papers on clinical and laboratory research in prostate cancer, and currently has more than $50M in peer reviewed funding. Dr. Gleave¹s major research focus involves the study of cellular and molecular mechanisms mediating progression of prostate cancer to its lethal stage of androgen independence, and use of this information to develop integrated multimodality therapies that specifically target these mechanisms. His research team employs state-of-the-art high-throughput approaches to target discovery, validation, functionalization, and therapeutic development. He has characterized the functional role of many survival genes in cancer progression, leading to several patented targeted inhibitors, and first-in-man trials of new anti-cancer drugs, OGX-011 and OGX-427 Dr. Gleave is a recipient of many awards, including the NCIC William Rawls Award for contributions to cancer control in Canada, Distinguished University Scholar designation by the University of British Columbia, BC Biotech Innovation and Achievement Award, and the BC Leadership Chair in Prostate Cancer Research.
Mr. Scott Cormack has over two decades of diverse experience in the biotechnology industry in executive management and venture capital.
Scott is the founding President and CEO of OncoGenex Technologies Inc. and became its full-time President and CEO in January, 2002. He has led OncoGenex through significant corporate milestones including serial rounds of private financing; leading the corporation through transition from pre-clinical through completion of multiple phase 2 clinical trials and through the development of a robust product candidate pipeline. In August, 2008 OncoGenex Technologies Inc. completed a successful reverse take over of Sonus Pharmaceuticals, Inc. to become a NASDAQ listed biotechnology company with Scott becoming the Chief Executive Officer of OncoGenex Pharmaceuticals, Inc.
In October, 2009, Scott was named Canada's Pacific Ernst & Young's Entrepreneur of the Year®, a high profile business award recognizing entrepreneurs that are building successful, dynamic businesses. In December, 2009, Scott led his team to complete a global collaboration and license agreement with global generic medicines giant, Teva Pharmaceutical Industries Ltd., to support the final stage of development of OGX-011. Scott has created a solid foundation for OncoGenex to maximize the broad potential of OGX-011 and a robust pipeline of product candidates, potentially bringing important treatment options to cancer patients.
Neil James Clendeninn Ph.D, MD
Dr. Clendeninn served as Corporate Vice President, Head of Clinical Affairs of Agouron Pharmaceuticals, Inc., a subsidiary of Pfizer Inc., from 1993 until his retirement in 2001. With Agouron, Dr. Clendeninn was responsible for development and growth of the Clinical Development Department from pre-clinical phase to phase IV, rapid delivery to market for Viracept, an HIV Protease Inhibitor. Under his leadership, the department grew to over 200 MDs, Ph.Ds and clinical pharmacologists, biostatisticans, data management group and a post marketing medical team. Previous to Agouron, Dr. Clendeninn served as Director of the Clinical Oncology Department for Burroughs Wellcome Company. His other past positions include assistant clinical professor in oncology at the University of North Carolina, senior staff member at the National Cancer Institute, and other general practice and academic-based positions. Dr. Clendeninn has led extensive research in areas that include chemotherapeutic multi-drug resistance, opiate receptors and photochemistry. He has written and co-authored numerous publications including, "The Approach to the Pre-clinical and Clinical Development of a Selective Matrix Metalloprotease Inhibitor (MMP); Prinomastat (AG3340)", July 2000. Dr. Clendeninn currently serves on the boards of Oncogenex Technologies Inc. and on the Board of Scientific Advisors for the National Cancer Institute. Dr. Clendeninn holds a BA Biology/Chemistry from Wesleyan University, CT, and a Ph.D Microbiology/Pharmacology and MD from New York University, NY.
Michael A. Martino, 53, is currently CEO of Arzeda Corp, a private enzyme design and development company based in Seattle, and has been a director of the Company since September 1998. In September 1998, he was appointed President and Chief Operating Officer of the Company and was appointed Chief Executive Officer of the Company in July 1999. In connection with the Arrangement, Mr. Martino resigned his officer positions with the Company effective August 21, 2008. From 1983 to 1998, Mr. Martino held numerous positions of increasing responsibility in strategic planning, business development, marketing and sales, and general management with Mallinckrodt, Inc., a global healthcare products company, including serving as Vice President and General Manager of the Nuclear Medicine Division. Mr. Martino holds a B.A. in business from Roanoke College and an M.B.A. from Virginia Tech. He sits on the Presidents Advisory Board of Roanoke College and is a member of the Board of Trustees of Cascadia Community College. In addition, Mr. Martino is a past Chairman of the Board of the Washington Biotechnology and Biomedical Association (WBBA).
Ms. Burris was appointed as a director of Sonus in May 2004. Ms. Burris is currently Senior Vice President and Chief Financial Officer of Trubion Pharmaceuticals, Inc, a position she has held since February 2006. From August 2005 to January 2006, Ms. Burris served as Senior Vice President and Chief Financial Officer at Dendreon Corporation. From January 2001 to July 2005, she served as Senior Vice President and Chief Financial Officer at Corixa Corporation, which was sold to GlaxoSmithKline in 2005. Ms. Burris had worked at Corixa since its inception in 1994, and prior to her last position at the firm, had served in various capacities of increasing responsibility in finance and operations. Prior to Corixa, Ms. Burris held several finance and strategic planning positions at The Boeing Company. Ms. Burris is on the Advisory Board of Albers School of Business and Economics at Seattle University. She received a Post Graduate Certificate in accounting and an MBA from Seattle University, and a B.S. from George Mason University. Ms. Burris received her Certified Public Accountant Certification from the State of Washington; however, she is no longer an active CPA.
Mr. Winstead has served as a director of Sonus since July 1995. Mr. Winstead is currently President and Chief Operating Officer of Cardinal Health Clinical Technologies and Services, (CTS) a subsidiary of Cardinal Health, Inc. Prior to his current position at CTS, he served as Group President of Clinical Services and Consulting and President of Pyxis Products, formerly known as AIS (Automated Information Services) since 1997. From 1991 to 1997, Mr. Winstead served as Executive Vice President of VHA, Inc., a performance improvement company serving health care organizations in the United States. Prior to his promotion to Executive Vice President, Mr. Winstead served in various capacities of VHA Supply Company, a subsidiary of VHA, Inc., including Vice President, Sales and Marketing, Senior Vice President, Chief Operating Officer and President from 1987 to 1991. Prior to joining VHA, Inc. in 1984, Mr. Winstead served in a variety of materials management and sales positions in several companies, including Ortho Instruments and Worthington Diagnostics. Mr. Winstead holds a B.S. from Delta State University.
show all
hide all
0.77
